New: Diploma joins FTSE 100 and Danaher to acquire Abcam – latest from the Quality Shares Portfolio

Archived article

Archived article: please remember tax and investment rules and circumstances can change over time. This article reflects our views at the time of publication.

Two of the 15 companies currently in the Quality Shares Portfolio have made the news this week. 

Yesterday, 30 August, it was confirmed industrial components supplier Diploma is joining the FTSE 100. 

Earlier this week, another company in the Quality Shares Portfolio, life sciences firm Danaher, made the headlines with its announced $5.7 billion acquisition of Cambridge-based biotech Abcam. 

I view these as encouraging signs for the Quality Shares Portfolio. 

Important: The information on individual company shares represents the view of Charlie as portfolio manager but it is not a personal recommendation to buy, sell or hold shares in any company. Experienced investors should form their own considered view or seek advice if unsure. Charlie personally holds shares in the companies mentioned and invests in the Quality Shares Portfolio. This article is original Wealth Club content.

Diploma3-test.jpgDiploma graduates to the FTSE 100

Diploma is a great example of the type of company I look for – operating below the radar of many investors, and rarely making headlines. 

The company has performed strongly since the launch of the Quality Shares Portfolio, reporting a 21% increase in revenues, including organic growth of 9%, in the nine months to June 2023.

This performance has been driven by several astute acquisitions, further entrenching Diploma’s niche market positions and providing entry to new fast-growing segments, like industrial automation. 

It is nice to see this progress being reflected in the share price performance, leading to its entry into the FTSE 100, although past performance isn’t a guide to the future. Diploma still has a relatively small share of its markets and a brimming acquisition pipeline. So, I believe there could still be more to come. 

Danaher-Charlie-800x200.jpgDanaher – agreement to acquire Abcam

Another company that made the headlines was Danaher. The company has agreed to pay c. $5.7 billion for Abcam, a leading provider of antibodies for scientific research, drug discovery and diagnostics, headquartered in Cambridge. The deal is expected to close next year, subject to regulatory and shareholder approvals.

I’ve followed Abcam for many years (it was previously on AIM, before listing on NASDAQ). I believe it has a great business model with high levels of recurring revenue and a trusted reputation amongst its customer base. Its antibodies are used extensively for scientific research, and I believe its long-term growth prospects are compelling. 

However, in recent years, Abcam’s performance has been disappointing. I think the main reasons for this are to do with its culture.

Abcam’s operational execution has left a lot to be desired. Missteps include a botched upgrade of an Enterprise Resource Planning (ERP) system, spiralling costs, expensive acquisitions and a loss of focus, leading to declining profit margins and falling returns on capital. 

Abcam’s founder, Jonathan Milner, recognises these issues. He is no longer involved in running the business but remains a major shareholder. Recently, he publicly criticised Abcam’s management and Board. This culminated in Abcam putting itself up for sale.

I suspect Danaher is well aware of these issues and sees scope to improve Abcam’s culture and operational execution. But clearly, this isn’t guaranteed. Changing the culture of a business is never straightforward and Danaher must tread carefully. 

That said, Danaher has a good track record of improving acquired businesses. This is largely due to a unique way of doing business called the Danaher Business System (DBS) which aims to improve operational processes and capture efficiencies in areas like supply chain, procurement, sales and back-end operations.  

The valuation Danaher is paying for Abcam (32x estimated 2024 EBITDA) strikes me as rather rich. But, if the DBS can be successfully applied, Danaher should be able to get Abcam’s profit margins moving in the right direction. When added to cost savings from the combination (which Danaher estimates at $75m annually by year five), it could lead to a significant acceleration in Abcam’s profits and justify the valuation multiple but there are no guarantees. 

Apply online now: Quality Shares Portfolio, managed by Charlie Huggins 

The Quality Shares Portfolio, managed by Charlie Huggins and exclusively available through Wealth Club, is a portfolio specifically designed for people who are genuinely interested in investing.

It’s a portfolio of 15-20 global businesses chosen for their resilience, financial strength and pricing power.

It is profoundly different from any other investment you might hold in two key respects. The first is the level of information, insight and transparency it provides (you can see an example here). The second is in the investing approach itself.

You can invest in the Quality Shares Portfolio online, if you’re a high net worth or sophisticated investor. The minimum investment is £10,000; you can invest in an ISA, SIPP or in a General Investment Account, subscribing new money or transferring existing investments.

Video of the week: interview with Charlie Huggins – What might higher interest rates mean for investors? (recorded Aug 2023)


Liked this article? Register to receive the next one straight into your inbox.

Wealth Club aims to make it easier for experienced investors to find information on – and apply for – investments. You should base your investment decision on the offer documents and ensure you have read and fully understand them before investing. The information on this webpage is a marketing communication. It is not advice or a personal or research recommendation to buy any of the investments mentioned, nor does it include any opinion as to the present or future value or price of these investments. It does not satisfy legal requirements promoting investment research independence and is thus not subject to prohibitions on dealing ahead of its dissemination.